I've been on the PSMAddition trial having had 5 of 6th infusions. PSA undetectable (<0.02) since June (it was 0.31 in early May when accepted into trial with relatively low burden PSMA-avid lesions).
Aug 4 CT/bone scans showed significant reductions in size and activity of lesions (prior to 3rd treatment). Oct scans showed smaller amounts of reductions in size and activity, but now only low grade activity in one area and very low grade activity in another area (prior to 5th treatment). Pluvicto could very well have helped, though ADT surely is playing a major role. Once the study data results get published out we can get a better idea of the relative contributions.
Overall I've tolerated the treatments well and platelets, neutrophils and other blood counts that take a minor to modest hit do bounce back afterwards, though not to pre-treatment levels.
Coming up to the 6th and final treatment, one of the docs is concerned about my borderline neutrophil counts (1.5) measured 1 week before the infusion and thought I should wait until they bounce back up before further treatment. Given the low PSA, good bone response and uncertainty regarding the effectiveness of a 6th Pluvicto treatment at this time, is the extra exposure to toxicity of the 6th infusion worth the opportunity (or uncertainty), however slight, to clean up as many bad cells as possible?